Search Results

. Kelsey CR Chino JP Willett CG . Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer . Int J Radiat Oncol Biol Phys 2007 ; 69 : 770 – 776 . 12. Javeri H Arora R Correa AM . Influence of induction

ductal carcinoma who has triple-negative disease and no BRCA1 or BRCA2 mutation identified would be an anthracycline and taxane-based regimen, such as the regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel

FOLFIRINOX [5-FU, leucovorin, irinotecan, and oxaliplatin] or gemcitabine) and the APACT study (NCT01964430; surgery followed by either gemcitabine/nanoparticle albumin-bound [nab]-paclitaxel or gemcitabine monotherapy). Turning to neoadjuvant therapy, Dr

recommended a patient-specific treatment plan that was not part of NCCN. Specific substitutions such as Capecitabine for 5-FU, Carboplatin for Cisplatin, and Paclitaxel for Docetaxel that were not part of NCCN were made to for patient tolerance of therapy

(Asia=71.1%; West=89.0%). The five most common 1L treatment regimens were cisplatin + 5-FU (27.4%), carboplatin + paclitaxel (8.4%), FOLFOX (8.0%), 5-FU (+leucovorin) (6.6%), and carboplatin + 5-FU (5.9%), although differences were observed by geography

to single-agent platinum therapy. 111 , 112 Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel and cisplatin/topotecan, have been extensively investigated in clinical studies. 111 , 112 , 114 – 116 A randomized phase

study evaluating carboplatin and 1 of 2 paclitaxel formulations in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) and a marginal PS found a significant difference in OS based on the geographic location of the patients. 8

://www.ama-assn.org/ama/pub/category/3113.html . Accessed November 2005 . 10. Langer CJ Leighton JC Comis RL . Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis . J Clin

cancer. These include nab -paclitaxel, eribulin, and ixabepilone. Evolution of HER2-Targeted Therapy The use of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, in combination with chemotherapy in the

CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or